Escola Paulista de Medicina
Postgraduate in Clinical Endocrinology

Article 3

As Selumetinib is a MEK1/2 inhibitor that has gained interest as an anti-tumor agent, the present study was designed to investigate autophagy involvement on Selumetinib-induced apoptosis in colorectal cancer (CRC) cells.

Methods: CRC cells death and cycle studies were assessed by AnnexinV-FITC and PI staining, respectively. Autophagy flux was analysed by Western Blot (LC3II and p62 protein levels) and retroviral infection of SW480 cells for siBecn1 RNA interference experiments. Confocal microscopy was used to determine mCherry-EGFP–LC3 distribution.

Key findings: The Selumetinib effects were concentration-dependent in SW480 cell line. Whereas 1 μM exerted an arrest in the cell cycle (G1 phase), higher concentrations (10 μM) induced cell death, which was accompanied by autophagy blockage in its last stages. Autophagy induction by Rapamycin (RAPA) increased cell survival, whereas pharmacology autophagy inhibition by Bafilomycin A1 (BAF), Chloroquine (CQ) or 3-Methyladenine (3-MA) increased Selumetinib-induced CRC cells death.

Conclusions: Altogether, these results suggest that autophagy plays a fundamental role in CRC cells response to Selumetinib. In addition, the combination of Selumetinib with autophagy inhibitors may be a useful therapeutic strategy to enhance its activity against colorectal tumours.

Artigos Relacionados - Artigos Científicos

30 Oct 2018 18:30

Endocr Rev. 2018 Oct 12. doi: 10.1210/er.2018-00126. [Epub ahead of print]
Skeletal and extra-skeletal [ ... ]

Artigos Cientificos
06 Nov 2020 15:45

Renata Peixoto‑Barbosa1,2, André F. Reis1 and Fernando M. A. Giuffrida1,2

1 Disciplina de Endocrinologia, [ ... ]

Artigos Cientificos
06 Nov 2020 15:54

Rubens Marcella-Neto a, João R. de Sá b, Cláudio S. Melaragno a, Adriano M. Gonzalez [ ... ]

Artigos Cientificos

© 2013 - 2019 Universidade Federal de São Paulo - Unifesp

Rua  Estado de Israel, 639 - Vila Clementino - São Paulo/SP - 04022-001 • 5089-9200 Ramal 2416